WARSAW, Ind. – Zimmer Biomet Holdings, Inc. (NYSE:), a leader in medical technology, has joined the Global Health Equity Network’s Zero Health Gaps Pledge, aimed at incorporating health equity into core business strategies. The company’s Health Equity division, formed in 2023, is advancing a 10-point plan to address disparities in orthopaedic care and track progress toward achieving equitable healthcare.
Ivan Tornos, President and CEO of Zimmer Biomet, expressed pride in signing the pledge, emphasizing the company’s long-standing commitment to reducing healthcare disparities and integrating health equity into its business model. The Health Equity division has established a strategic advisory board and is developing a Community Centered Care framework to improve access to quality care in underserved communities.
Edmond Davis, Senior Director of the Health Equity division, highlighted the shift from philanthropic efforts to a business strategy that directly tackles social determinants of health. The division’s initiatives include increasing minority representation among orthopaedic surgeons and collaborating with healthcare institutions to enhance patient outcomes.
Zimmer Biomet has historically contributed to health equity through its philanthropic initiatives, including the independent organization Movement is Life, which addresses musculoskeletal health disparities.
The information in this article is based on a press release statement from Zimmer Biomet Holdings, Inc.
As Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reinforces its commitment to health equity, the company’s financial health also remains a focal point for investors. Zimmer Biomet’s market capitalization stands at a robust $25.66 billion, reflecting its significant presence in the medical technology sector. The company’s price-to-earnings (P/E) ratio has adjusted from 24.95 to a more favorable 21.46 over the last twelve months as of Q4 2023, suggesting increased earnings efficiency and investor confidence.
InvestingPro Tips indicate that Zimmer Biomet’s management has been actively buying back shares, a sign that company leadership is confident in the firm’s future prospects. Additionally, the stock is known to exhibit low price volatility, providing a level of stability in an investor’s portfolio. These factors, coupled with a strong return over the last three months, where the company has seen a 16.72% price total return, underscore Zimmer Biomet’s…